Elanco Animal Health Incorporated (ELAN) has a MoatMap StockRank of 78/100 based on Quality (48/100), Value (44/100), and Momentum (70/100) factor scores. The current signal is BUY. Elanco Animal Health is a highly leveraged turnaround story in the animal health sector. Under the Terry Smith lens, we strictly avoid turnarounds and heavily indebted balance sheets.
Elanco Animal Health Incorporated is a global leader in animal health, dedicated to developing, manufacturing, and marketing innovative products and solutions for pets and livestock across more than 90 countries. The company establishes a strong competitive moat through its diversified portfolio of essential parasiticides, vaccines, and therapeutic products, coupled with significant R&D investment and deep relationships with veterinarians and livestock producers. Elanco's focus on animal well-being and food security positions it as a resilient player in the growing animal health market.
| Price | $24.57 |
| Market Cap | $12.0B |
| P/E (Forward) | 18.81 |
| Price/Book | 1.75 |
| Return on Equity | -3.8% |
| Return on Invested Capital | -0.0% |
| Debt/Equity | 66.15 |
| Gross Margin | 55.1% |
| Operating Margin | 12.3% |
| Revenue Growth | 14.9% |
| Free Cash Flow | $692M |
Elanco Animal Health Incorporated operates in the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector (United States).